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Abstract: Malaria is a life-threatening parasitic infection occurring in the endemic areas, primarily
in children under the age of five, pregnant women, and patients with human immunodeficiency
virus and acquired immunodeficiency syndrome (HIV)/(AIDS) as well as non-immune individuals.
The cytoadherence of infected erythrocytes (IEs) to the host endothelial surface receptor is a known
factor that contributes to the increased prevalence of severe malaria cases due to the accumulation of
IEs, mainly in the brain and other vital organs. Therefore, further study is needed to discover a new
potential anti-adhesive drug to treat severe malaria thus reducing its mortality rate. In this review,
we discuss how the aptamer technology could be applied in the development of a new adjunct
therapy for current malaria treatment.
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1. Introduction
Malaria is a life-threatening disease caused by parasites transmitted to humans through the bite
of infected Anopheles mosquitoes. The disease mostly affects children, pregnant women, non-immune
persons, and individuals with chronic diseases such as human immunodeficiency virus and acquired
immunodeficiency syndrome (HIV/AIDS). Malaria causes complications such as severe anemia,
metabolic acidosis, and cerebral malaria, often leading to death if not treated within 24 h [1,2].
The World Health Organization (WHO) reported there were 438,000 deaths caused by malaria
worldwide, especially in the endemic areas such as Africa [3]. In humans, malaria is caused by five
distinct Plasmodium species, namely P. falciparum, P. vivax, P. malariae, P. knowlesi, and two sub-species
of Plasmodium ovale (P. o. curtisi and P. o. wallikeri) [4–6]. Of these, P. falciparum causes the most severe
disease due to higher parasitemia, and it is responsible for the massive burden of global mortality and
morbidity [7,8]. Despite extensive interventions by WHO to prevent, control and eliminate malaria,
the transmission of the disease continues in many countries around the world. The interventions
consist of an array of drugs, insecticides, diagnostics, and understanding of the breeding site criteria [9].
Other factors that contribute to the prevalence of malaria include increased transmission risks among
people who are non-immune to the disease, the growth in international travel and migration, and the
escalation of drug-resistant parasites [10]. However, the underlying mechanism that contributes
to malaria severity in a patient is still not well understood, adding to the difficulty in curbing the
disease’s progression.
Several drugs are available for malaria treatment including chloroquine, sulfadoxine/pyrimethamine
(SP), and quinine, which are working well in many parts of the world. Unfortunately, there is a
grave concern that the malaria parasites have developed a widespread resistance to anti-malarial
drugs, especially in the endemic regions [11,12]. Anti-malarial drug resistance has been observed
for P. falciparum, P. vivax and P. malariae in most parts of the world [13]. The SP resistance is seen
in Papua New Guinea, Thailand, Indonesia, Madagascar, Iran, Afghanistan, India, and Pakistan
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whereas chloroquine resistance is observed in Southeast Asia and South America, including Africa
and India [14,15]. Though the artemisinin-based combination therapies (ACTs) were used to treat
malaria globally, the artemisinin-resistant parasite was detected when treatment was given to
symptomatic malaria patients, and clearance of the parasite from the bloodstream was delayed [16].
The artemisinin-resistant parasite was first discovered in the province of Pailin and these days it can
be found in several other countries such as Cambodia, Myanmar, Thailand, and Vietnam. Therefore,
the understanding of the disease epidemiology and genetics of malaria are crucial in order to control
the spread of parasite resistance to anti-malaria drugs [17–20].
As the threat of anti-malarial drug resistance grows, there is increasing pressure to develop
alternative treatments. Therefore, taking into consideration the ability of the parasites to infect
erythrocytes, the development of an anti-adhesive drug as an adjunct therapy to treat severe malaria
could be considered. In this review, we shall focus on how the aptamer technology can be explored as
a potential anti-adhesive therapy for malaria.
2. Pathogenicity of Malaria
Malarial parasites have a complex life cycle involving sexual and asexual reproductive stages.
The sexual stage takes place inside the mosquito vector. An infected female Anopheles mosquito injects
a sporozoite of P. falciparum into the human host, which invades the host’s hepatocytes. The asexual
life cycle of the parasite begins within 8 to 10 days, when merozoites are formed. The merozoites
are then released into the bloodstream and rapidly invade normal erythrocytes. During the asexual
blood stage, the merozoites develop into the ring-stage, the pigmented-trophozoite stage, and the
schizont-stage inside the infected erythrocytes (IEs) within 48 h. The cycle is repeated through the
replication and the release of new merozoites to invade other uninfected erythrocytes. Repeated cycles
of IEs invasion, replication, and merozoite release result in an exponential growth of the parasite
leading to the progression of the disease.
Most of the symptoms and clinical complications of malaria are observed during the asexual
stage. It starts with a high fever and is associated with “flu-like” symptoms followed by a headache,
chills and vomiting [21]. However, these symptoms may be mild and difficult to recognize as
malaria, even if the falciparum parasites are detected in the blood, especially in uncomplicated
malaria [22]. During the asexual stage, the IEs containing pigmented-trophozoite and schizont express
a protein-derived adhesion molecule on the surface, P. falciparum erythrocyte membrane protein 1
(PfEMP1). The transported protein on the surface of the red blood cell is known to play an important
role in the adhesion mechanism to host endothelial tissues and stimulate immune recognition [23–25].
Unfortunately, sequestration of the IE to the microvascular surface protein will cause obstruction
to the vessel that would subsequently contribute to the development of severe malaria. WHO has
defined severe malaria as an abnormal metabolic process, especially in the blood system that creates
an acidic condition, hypoxia, and cell necrosis and apoptosis that could be lethal to the infected
patient [21]. Figure 1 shows the effect of IE sequestration to various surface receptors such as the
complement receptor 1 (CR1), intercellular adhesion molecule 1 (ICAM-1), chondroitin sulfate A (CSA),
heparan sulphate, cluster of differentiation 36 (CD36), and endothelial protein C receptor (EPCR),
which determine the disease outcomes.
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Figure 1. The effect of infected erythrocytes sequestration by various endothelial surface receptors 
and their disease phenotype. The diagram is modified from Penman et al. (2008) and Cabrera et al. 
(2014) [26,27]. 
3. Cytoadherence of Infected Erythrocyte 
Cytoadherence is believed to be one of the factors that cause severe malaria. In cytoadherence, 
IEs acquire novel adhesive properties which are sequestration (interaction of IEs with endothelial 
receptor ligands), rosseting (interaction of IEs with uninfected erythrocytes), and platelet clumping 
(interaction of IEs with platelets causing them to bind to other IEs) as shown in Figure 2 [28]. PfEMP1 
is involved in the cytoadherence process which enables the IEs to bind to a number of host receptors 
on the endothelial cell through tethering, rolling, and adhesion of IE on the surface [21,29,30].  
The cytoadherence of IEs to the host endothelial surface receptor prevents parasite clearance by the 
spleen [21,31]. 
 
Figure 2. The cytoadherence of infected erythrocytes to red blood cell and endothelial cell promotes 
the formation of rosetting, sequestration and platelet clumping. These infected erythrocytes (IEs) bind 
to a number of host receptors on the endothelial cell through tethering, rolling, and adhesion of IE on 
the surface. This cytoadherence of IEs to the host endothelial surface receptor prevents parasite 
clearance by the spleen. The diagram is modified from Rowe et al. (2009) [21]. 
CD36 is known as a multiligand scavenger receptor that mediates the binding and uptake of a 
wide variety of particulate ligands such as oxidized low-density lipoproteins, bacteria, β-amyloid 
plaque, and apoptotic cells by macrophages [32,33]. In malaria, cytoadherence mediated by CD36 
may contribute to the dysfunction of certain organs such as lung, liver, and kidney by impairing the 
microcirculatory blood flow [34–36]. Interestingly, this protein is expressed at low level in the brain 
Figure 1. The effect of infected erythrocytes sequestration by various endothelial surface receptors
and their disease phenotype. The diagram is modified from Penman et al. (2008) and Cabrera et al.
(2014) [26,27].
3. Cytoadherence of Infected Erythrocyte
Cytoadherence is believed to be one of the factors that cause severe malaria. In cytoadherence,
IEs acquire novel adhe ive prope ties which are sequestration (interaction of IEs with endothelial
receptor ligands), rosse ing (interactio of IEs with uninfected erythrocytes), and platelet clumping
(interaction of IEs with platelets causing them to bind to other IEs) as shown in Figure 2 [28].
PfEMP1 is involved in the cytoadherence process which enables the IEs to bind to a number of host
receptors on the endothelial cell through tethering, rolling, and adhesion of IE on the surface [21,29,30].
The cytoadherence of IEs to the host endothelial surface receptor prevents parasite clearance by the
spleen [21,31].
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Figure 2. The cytoadherence of infected erythro t red bl od cell and endothelia cell promotes
the formation of r setting, sequestration and platelet cl ping. These infected erythrocytes (IEs) bind
to a number of host receptors on the endothelial cell through tethering, rolling, and adhesion of IE
on the surface. This cytoadherence of IEs to the host endothelial surface receptor prevents parasite
clearance by the spleen. The diagr m i modifi d from Rowe et al. (2009) [21].
CD36 is known s a multiligand cavenger receptor that mediates he binding and uptake of a
wide v riety of particulate igands such s oxidized low-density lipoproteins, bac ria, β-amyloid
plaque, and apoptotic cells by macrophages [32,33]. In malaria, cytoadherence mediated by CD36
may contribute to the dysfunction of certain organs such as lung, liver, and kidney by impairing the
microcirculatory blood flow [34–36]. Interestingly, this protein is expressed at low level in the brain
where it is not inducible by inflammatory cytokines and also indirectly supports the cytoadhesion of
the IEs to the microvascular brain, therefore preventing severe malaria [28,37].
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In cerebral malaria (CM), it has been shown that there is an association between IE binding
to ICAM-1, although there is no explanation on how the mechanism of IEs cytoadherence in the
brain leads to CM [28,38]. A recent study has successfully identified the conserved domain cassette
(DC) structure, DC4, that plays a role in PfEMP1 binding to ICAM-1 by the duffy-binding–like
(DBL), DBLβ3_D4 (domain 4). This DC4 has also been shown to be linked to the pathogenesis of
the severe form of the disease [39,40]. A study by Berger et al. showed that DC5-containing PfEMP1
bound to platelet and endothelial cell adhesion molecule 1 (PECAM1) has been associated with
CM [41,42]. However, the binding of IEs to PECAM1 was also found in uncomplicated malaria
patients, where DC5-containing PfEMP1 was also expressed by the parasite when not selected for
adhesion to brain endothelial tissue [43–45].
Several studies have demonstrated that endothelial dysfunction and resulting inflammation
preferentially affected the brain, but the mechanism behind it is still unclear [28]. Post-mortem studies
conducted by several groups have shown a small haemorrhage in the brain which was associated with
the platelets and thrombin or fibrin, but their role in the coagulation and specificity in CM is still being
debated [46–48]. The endothelial protein C receptor (EPCR) and thrombomodulin (TM) play a major
role in regulating the coagulation, inflammation, endothelial barrier function, and neoprotection in
the anticoagulant protein C pathway [49–51]. These proteins are expressed at low level in the brain
compared to other organs [52,53].
The association between the loss of local EPCR and TM with CM are caused by the sequestration
of IEs, which disturbs the coagulation and inflammatory mechanism [48]. In an excessive clotting
cascade, the thrombomodulin is bound to the thrombin and forms a thrombomodulin-thrombin
complex. This complex then activates protein C to form activated protein C (APC) and this process is
strongly accelerated by EPCR [54,55]. The APC can be exerted as anticoagulant, anti-inflammatory,
antiapoptotic, and vasculoprotective signal through the protease activated receptor 1 (PAR1). In CM,
the protein C pathway becomes impaired causing the level of thrombin to increase and eventually
distrupt the endothelial barrier function, increasing the inflammation and coagulation signals.
Furthermore, Lavsteen et al. recently revealed that PfEMP1 domain cassettes 8 and 13 can bind
to EPCR endothelial receptor near or at the same region as APC, which can inhibit APC-mediated
EPCR-dependent cytoprotective effects on endothelial cells [43,45,56]. The authors also demonstrated
that the EPCR displayed a stronger binding in children with severe malaria compared to children who
have uncomplicated malaria.
4. Introduction to Aptamer Technology
Since 1990, many studies have been conducted using the RNA molecules that specifically bind to
many targets, including small molecules, proteins, enzymes, nucleic acids, protein receptors, viruses,
and considerably more targets [57]. Single-stranded nucleic acid (ssDNA or RNA) can be folded to
form a complex secondary and tertiary structure which can bind to different compounds, molecules
and proteins [58]. The term aptamer is derived from Latin and Greek words which are “Aptos”—to fit,
and “meros”—part of the region [59]. Aptamers bind to their target via an “induced fit” mechanism,
which allows them to tightly bind to the target at high specificity and affinity, similar to antibodies
(they’re also known as chemical antibodies) [60–62]. Interestingly, aptamers bind to their target through
hydrogen bonding, electrostatic interactions, van der Waals forces and shape complement; similar to
antibody-antigen recognition and complex formation [63]. Even though both DNA aptamers and RNA
aptamers can form complex structures, the RNA aptamer can form more diverse three dimensional
(3D) structures compared to DNA aptamers, as RNA contain 2′-OH (hydroxide) group on their ribose
sugar [61,64,65].
SELEX (Systematic Evolution of Ligand by Exponential Enrichment) is a method used to isolate
aptamers that specifically bind to a target with high affinity through a repetitive amplification and
selection process. Previous studies revealed that the SELEX method has been used extensively to isolate
high affinity ligands that bind at picomolar and low nanomolar affinities to a wide variety of proteins
and cell surface epitopes [66]. For instance, SELEX has been used to isolate cluster of differentiation 4
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(CD4), L-selectin, Vascular Endothelial Growth Factor (VEGF), Epidermal Growth Factor Receptor
(EGFR) as well as complex targets such as the red blood cell membrane, the membrane-bound nicotinic
acetylcholine receptor, and whole virus particles [66–68].
In the SELEX technology, there are several crucial steps which must be followed until the aptamer
with high specificity and strong affinity to a target can be isolated. (i) The SELEX process starts with
a chemical synthesis of a randomized oligonucleotide containing 1014 to 1016 unique randomized
sequences flanked by primer binding regions [56,66]. Usually in SELEX, the length of RNA or ssDNA
is within the range of 56 to 120 base pairs depending on how complex the starting nucleic acid pool
needs to be [67]. For DNA aptamer selection, the dsDNA should be separated to obtain ssDNA by
using several methods such as asymmetric PCR, biotin-streptavidin separation, lamba exonuclease
digestion and size-based separation by denaturing polyacrylamide gel electrophoresis (PAGE) [69–71].
However, an additional method is needed to synthesize the RNA pool from the DNA pool through
in vitro transcription for RNA aptamer selection, as commercialized production is expensive compared
to in-house production. The sense primer should be included with the T7 RNA polymerase promoter
to allow in vitro transcription to occur [68–70].
After that, (ii) the oligonucleotide library is incubated with the target molecules to allow the
binding to occur. The selection incubation is commonly performed at room temperature or on ice
(4 ◦C). Other conditions depend on the target aptamer assay development. After the incubation,
(iii) the aptamer that bound to the target is separated from unbound aptamer. Plentiful methods have
been established, from simple methods (e.g., nitrocellulose filter, affinity chromatography column,
microtitre plate-based method) to using high-technology instruments (e.g., Surface Plasmon Resonance
(SPR), Capillary Electrophoresis (CE) and flow cytometry) to partition the unbound aptamer from
target-bound aptamer [72–75]. The development of new high-technology instruments has helped
scientists to do a SELEX process in only a few hours, instead of over several weeks [76]. The eluted
bound aptamers are amplified through a polymerase chain reaction (PCR) and are used for another
round of the SELEX cycle. However, for the RNA aptamer, the collected RNA pool should be reverse
transcribed before amplification using PCR. The enrichment of the SELEX cycle can be monitored
(iv) by adding a fluorochrome reporter at the 5′-sense primer sequence for a DNA aptamer. An RNA
aptamer can be tagged either at the 3′-end or the 5′-end, which is an alternative way for radioactive
labelling [77,78]. Figure 3 shows the comparison of methods between RNA aptamer and DNA aptamer
development. (v) After several iterative rounds of SELEX, the final products of target-bound aptamer
are cloned and subjected to sequencing. The sequences are aligned and clustered based on their
similarities of homologous sequences and common motif structures. Further investigation is needed to
identify the most prominent clusters that bind to a target as potential aptamer candidates.
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selected molecules requires an additional step to produce an RNA strand from single-stranded DNA
through DNA transcription. Reverse transcription is needed to produce single-stranded DNA to
produce an RNA pool for the subsequent SELEX cycle; (B) A separation step is required to produce
single-stranded DNA from double-stranded DNA prior to the DNA aptamer selection. Commonly,
the pool of aptamers begin with 1013 to 1014 random sequences which are then enriched into several
groups f aptamers th t specifically to their target. This can be achi ved by equencing the final bound
product of SELEX and aligning the sequ nces. Further study is needed to measure the binding affinity
of enriched aptamers to the target molecules.
5. Aptamers as Therapeutic Agents Compared with Antibodies
Most of the current therapeutic and diagnostic applications use a monoclonal or polyclonal
antibody against a specific antigen or protein. Since aptamer technology was discovered in the
early 1990s, numerous studies have been con cted to isolate specific aptamers to specific molecules,
especially int rcellular molecules, which are unreachable by an antibody. Aptamers have more
advantages than antibodies in terms of productio , stability, binding affinity, small ize, nd less
immunogenicity [79,80].
Production of monoclonal antibodies (mAb) normally uses a vertebrate organism such as a
mouse, goat, or rabbit, and injecting the animals with a specific antigen to produce a specific
antibody. Aptamer production does not require organisms for oligonucleotide synthesis [81]. Instead,
instruments that are commonly used in the molecular laboratory such as a thermal cycler are utilised.
Therefore, oligonucleotide synthesis offers a huge benefit in manipulating the process of direct
evolution through in vitro selection of the aptamer for the target molecules.
Moreov r, the in vitro production of monoclonal antibodies (mAb) using mammalian cell
culture is laboriou and very expensive. The process involves large number of coloni s and
requires confirmation of antibody activity by immunoassay in each new batch produced, as the
same antibodies tend to change in different batches [62,79,82]. Since the aptamer is chemically
synthesized, it can be synthesized with greater accuracy and reproducibility with a lower variation [83].
Aptamer development companie such as Archemix’s Stanton have shown that the manufacture
of custom aptamers will cost $50 or less per gram on manufacturing scale [84]. Custom aptamer
manufacturing can be completed within two days as compared to months for human monoclonal
antibody production at an average cost $300/g [84,85].
As mentioned earlier, an aptamer can reach target molecules which are difficult to reach by
antibodies such as those inside tissues or intercellular molecules due to their size (8–25 kDa) compared
to the antibody (approximately 250 kDa). The intercellular molecules allow the aptamer to penetrate
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the tissue more efficiently to reach their target in vivo in comparison to the larger size of the
protein antibody.
Since aptamers are a single stranded nucleic acid, theoretically they should not be recognised by
the human immune system as foreign molecules. However, a study by Eyetech Study Group showed a
slight immunogenicity of a VEGF-specific aptamer when given to a monkey at a 1000-fold higher dose
than the therapeutic dose [86]. This is comparable to antibodies which are significantly immunogenic,
especially following repeated dosing [87].
Furthermore, the antibody is well known for its irreversible denaturation that can cause it to lose
its binding ability to a specific target, as its tertiary structure is lost when exposed to high temperatures.
Aptamers are more thermally stable even after 95 ◦C denaturation [79,88]. Thus, aptamers are able to
recover their native structure over repeated cycles of denaturation and renaturation that allow them to
be used under a wide range of assay conditions [83].
A limitation of aptamers compared to antibodies is that the RNA aptamers are susceptible to
nuclease degradation at the 2′-OH on the ribose sugar of nucleic acid. Nevertheless, it still can be
improved through chemical modification by substitution of the 2′-OH group with 2′-fluoro pyrimidine,
2′-amino pyrimidine, or 2′-O-methoxy pyrimidine and purine. This modification not only increases
nuclease resistance but also allows stronger aptamer binding with the target and increased binding
specificity [89].
6. Discovering Anti-Cytoadhrence through Aptamer Technology
In terms of aptamer generation for anti-adherence of the malaria parasite to the microvascular
endothelial surface receptor, the target should be identified. In other words, it is crucial to determine
whether a purified recombinant protein or a whole cell surface should be used. Similar to protein-based
antibody development, the recombinant protein of a selected surface receptor such as ICAM-1, CD36,
and VCAM-1 can be expressed in the prokaryotic or eukaryotic system by tagging them with certain
affinity molecules such as histidine, immunoglobulin, glutathione-S-transferase, and streptavidin
for protein purification and surface immobilization purposes [39,90,91]. However, often a highly
glycosylated protein, purified protein or peptide cannot be folded into the correct 3D structures in their
native conditions due to post-translational modification [92]. The newly synthesized aptamer may be
incapable of recognizing the selected target which would result in the failure of selection. Therefore,
a modified SELEX technology using whole living cells or Cell-based SELEX (Cell-SELEX) could be
used to increase the chances of success [93].
However, a previous study revealed that Cell-SELEX caused a low aptamer enrichment efficiency
because a number of proteins or molecules co-expressed on the cells [61]. This might cause the
selectivity of the aptamer to the target to become less specific, and cause a low affinity to the target.
To overcome this problem, another method of SELEX can be used by combining the Cell-SELEX method
with a protein-based SELEX known as Cross-Over SELEX or Hybrid-SELEX. This Hybrid-SELEX
method has been used to isolate an RNA aptamer specific to Tenascin-C and a DNA aptamer specific
to CD30-expressing lymphoma tumour cells, respectively [94,95]. When using the Cross-Over SELEX,
the aptamer pool is initially incubated with a cell-expressing selected protein or molecule, and then
the bound aptamer is collected. After amplification, the subsequent aptamer is incubated with a
purified protein or molecule of interest. This approach allows for higher selectivity of the aptamer in
recognizing and binding to its target protein.
Therefore, a potential anti-cytoadherence could be developed using Cross-Over SELEX by
combining the purified recombinant protein (e.g., ICAM-1 protein) and human umbilical vein
endothelial cells (HUVEC). HUVEC is a cell line that expresses small levels of ICAM-1 but is
CD36-deficent. However, tumour necrosis factor (TNF) will promote the up-regulation of expression
of ICAM-1 [96,97]. After several iterative rounds of selection against recombinant ICAM-1 protein
and HUVEC, the isolated aptamer is then further investigated for its ability to inhibit and reverse the
binding of IEs to ICAM-1 using static or flow assay.
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Study on inhibiting the IEs binding property to isolated aptamers can be performed by incubating
the mature stage of Plasmodium IEs culture with immobilized recombinant ICAM-1 protein or HUVEC
which previously blocked the isolated aptamer. After incubating and washing steps, the remaining
parasite will be calculated and compared with control (untreated with aptamer). Aptamer that shows
significant reduction in the number of bound IEs might possess the cytoadherence inhibition property.
Study on reversing the IEs binding property can be performed by introducing the aptamer candidate
into the assay containing IEs culture bound to immobilized protein or cells. Any significant reduction
in the number of bound IEs might indicate that the aptamer has the ability to reverse the IEs binding
to the receptor protein.
The potential aptamer that is able to inhibit or reverse the binding of IEs from endothelial protein
receptor can allow the clearance by the spleen and relieve microvascular obstruction in severe malaria
patients [21]. This adjunct therapy might have a clinical benefit to reduce mortality rates for severe
malaria even after giving anti-malaria drugs [98].
7. Current Aptamer Development for Malaria Therapy
Even though the mechanism on how parasite cytoadherence to microvasculature can result in the
severity of the malaria disease is yet to be comprehended, post-mortem studies have shown that the
presence of IE in the microvessels is associated with the disease’s pathology [22]. The cytoadherence
and rosetting of IE to endothelial surface receptors such as ICAM-1, CD36, heparin and chondroitin
sulfate A by PfEMP1 could be used to innovate a new therapy that has the capability to block or
reverse the binding of IEs. By identifying the conserved region of PfEMP1 which is responsible
for rosette formation, Barfod et al. successfully isolated the specific RNA aptamer targeting DBLα
after eight rounds of selection starting with 5 × 1014 unique sequences [99]. They have shown that
the isolated RNA aptamer reduced rosette formation by 35% at 33 nM concentration and by 100%
at 387 nM concentration during an in vitro study using a high rosette-forming strain, P. falciparum
FCR3S1.2 [99,100].
Current treatment of malaria involves drug usage such as chloroquine, quinine,
sulfadoxine/pyrimethamine, and artemisinin to disturb the biological mechanism of the live parasite
in the human blood cell from surviving due to the heme toxicity. The drugs prevent the heme from
crystallizing to hemozoin through the formation of deprotonated drug, which caps the hemozoin
to prevent further crystallization of the heme. This heme molecule is highly toxic to the cell and
leads to the dysfunction of the membrane resulting in cell lysis and parasite cell autodigestion.
Therefore, to avoid this toxic molecule, the heme molecules (Fe2+) oxidize to form hemozoin (Fe3+)
which precipitates the inside of the parasite vacuoles, also known as a malaria pigment [101].
Using the hemoglobin degradation mechanism, Okazawa et al. successfully isolated the DNA
aptamer that specifically binds to the heme molecules to interfere with the heme-detoxification in
P. falciparum [102,103]. The DNA aptamer selection was carried out at pH 7–8. Fortunately, the selected
heme-binding DNA aptamers were able to bind similarly to the heme molecules at an acidic pH,
where the parasite growth was significantly reduced after 72 h in the culture when compared to the
non-heme binding DNA aptamer [104]. This finding showed promise for the isolated DNA aptamer’s
probability of being used as a therapeutic tool to improve the antimalarial drugs. Table 1 shows the
summary of previously developed aptamers for malaria treatment targeting parasite expressed protein
(DBLα) and heme molecules.
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Table 1. Summary of previously developed aptamers for malaria treatment.
Aptamer Target Function Result Reference
RNA
Surface protein of
PfEMP1—
DBLα domain
To disrupt the rosette
formation between
infected erythrocyte with
normal erythrocyte.
Isolated RNA aptamer
reduced rosette formation by
35% at 33 nM concentration
and 100% reduction at 387 nM
concentration during in vitro
study using high
rosette-forming strain,
P. falciparum FCR3S1.2
[99]
DNA Heme group
To interfere with
heme-detoxification and
growth of P. falciparum in
infected erythrocyte.
Parasite growth was
significantly reduced after
72 h in a culture when
compared with the control
[102]
8. Conclusions
In the South East Asian Quinine Artesunate Malaria Trial (SEQUAMAT) study, Dondrop and
colleagues revealed that there is correlation between high parasite burdens in the blood vessel and the
severity of malaria where 15% of patients died even after they were given an artesunate treatment [105].
The study indicated that there is an accumulation of IEs in the tissues which were linked to the disease’s
severity [105]. This proved that P. falciparum cytoadherence has a key role in the pathogenesis of
life-threatening malaria and it could be targeted by a drug or a small molecule therapy.
Several mAb were discovered to be capable of blocking or inhibiting IE cytoadherence such as
mAb OKM5 which can bind to an epitope of the ectodomain region of CD36 to block the cytoadherence
of IEs to CD36 [106]. Meanwhile, mAb 15.2 against the L42 loop of domain 1 of ICAM-1 has been
found to be able to inhibit the cytoadherence of IEs to ICAM-1 [107]. However, mAb also possess
some limitations such as high immunogenicity, increased cost of production, large in size, thermally
unstable and difficult to chemically modify [108].
Therefore, discovering a new technology such as aptamer development is vital to inhibit and
reverse parasite binding on endothelial cells. Current aptamer development for malaria targets PfEMP1
which is associated with rosette formation and heme metabolism. Unfortunately, an aptamer targeting
the host endothelial surface receptors to block or reverse the binding of IEs is yet to be explored. In this
review, a number of endothelial receptors were mentioned and could be potentially used for future
studies to isolate the aptamer to select the receptor protein, a potential for the malaria anti-adherence.
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